The development of encapsulated cell technologies as therapies for neurological and sensory diseases

Simple item page
dc.contributor.authorZanin, Mark
dc.contributor.authorPettingill, Lisa
dc.contributor.authorHarvey, Alan
dc.contributor.authorEmerich, Dwaine
dc.contributor.authorThanos, Christopher
dc.contributor.authorShepherd, Robert
dc.date.accessioned2014-03-31T23:09:47Z
dc.date.available2014-03-31T23:09:47Z
dc.date.issued2012-02
dc.description.abstractCell encapsulation therapies involve the implantation of cells that secrete a therapeutic factor to provide clin- ical benefits. The transplanted cells are protected from immunorejection via encapsulation in a semiperme- able membrane. This treatment strategy was originally investigated as a method for protecting pancreatic islets from immunorejection, thus allowing them to secrete insulin as a chronic treatment for diabetes. Since then a significant body of work has been conducted in developing cell encapsulation therapies to treat a variety of different diseases. Many of these conditions involve neurodegeneration, such as Alzheimer's and Parkinson's disease, as cell encapsulation therapies have proven to be particularly suitable for delivering thera- peutics to the central nervous system. This is mainly because they offer chronic delivery of a therapeutic and can be implanted proximal to the affected tissue, bypassing the blood brain barrier, which is impermeable to many agents. Whilst these therapies are not yet widely available in the clinic, promising results have been obtained in several advanced clinical trials and further developmental work is currently underway. This review specifically examines the development of encapsulated cell therapies as treatments for neurological and sensory diseases and evaluates the challenges that are yet to be overcome before they can be made available for clinical use.en_US
dc.description.sponsorshipThe authors acknowledge funding support from the National Health and Medical Research Council of Australia, the Garnett Passe and Rodney Williams Memorial Foundation, the Western Australia Neurotrauma Research Program and the Victorian Government's Operational Infrastructure Support Program.en_US
dc.identifier.citationZanin, M. P., Pettingill, L. N., Harvey, A. R., Emerich, D. F., Thanos, C. G., & Shepherd, R. K. (2012). The development of encapsulated cell technologies as therapies for neurological and sensory diseases. Journal of Controlled Release, 160, 3–13.en_US
dc.identifier.urihttp://repository.bionicsinstitute.org:8080/handle/123456789/68
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectEncapsulationen_US
dc.subjectNeurotrophinen_US
dc.subjectAlzheimer's Diseaseen_US
dc.subjectParkinson's Diseaseen_US
dc.subjectHearing Lossen_US
dc.subjectRetinal Degenerationen_US
dc.titleThe development of encapsulated cell technologies as therapies for neurological and sensory diseasesen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Zanin Encapsulated Cell Technologies.pdf
Size:
453.49 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
BI publications